# Calcium-Phosphorus Regulation Therapy on Heart Valve Disease

Study · id `cardio:ct-nct06660524` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06660524](<https://clinicaltrials.gov/study/NCT06660524>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06660524

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 196 participants.

## Technical summary

Registry record NCT06660524. Randomized; no masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 196 participants (planned count; ClinicalTrials.gov record NCT06660524, source copy `cardio:ctgov-nct06660524-2024-10-28`, retrieved 2026-11-18)
- Started: 2024-03-01 (actual) (ClinicalTrials.gov record NCT06660524, source copy `cardio:ctgov-nct06660524-2024-10-28`, retrieved 2026-11-18)
- Primary completion: 2025-06 (anticipated) (ClinicalTrials.gov record NCT06660524, source copy `cardio:ctgov-nct06660524-2024-10-28`, retrieved 2026-11-18)
- Completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT06660524, source copy `cardio:ctgov-nct06660524-2024-10-28`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT06660524, source copy `cardio:ctgov-nct06660524-2024-10-28`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06660524-2024-10-28`, retrieved 2026-11-18)

## The registry's words

- Brief title: Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
- Condition: Degenerative Heart Valve Disease
- Condition: Heart Valve Calcification
- Condition: Chronic Kidney Disease(CKD)
- Condition: Calcium-Phosphorus Metabolism Disorders
- Intervention (Drug): Sevelamer
- Intervention (Drug): Calcium carbonate
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: 4324989369e9621689f0ff7dd40788da7d858f01084671b410ad77a7296fe7f3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
